CNP520 in Preclinical Alzheimer’s Disease Participants
CNP520 in Preclinical Alzheimer’s Disease Participants at Risk for the Onset of Clinical Symptoms of Alzheimer’s Disease (“Generation II”)
What is the “Generation II” study?
This is a five to seven year study of approximately 2,000 cognitively healthy adults, ages 60-75, at risk of developing symptoms of Alzheimer’s because they inherited at least one copy of the apolipoprotein E (ApoE4) gene from one of their parents.
What is the Purpose of “Generation II”?
The purpose of this study is to test whether an investigational drug called CNP520, can slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at risk of developing clinical symptoms based on their age and genotype. Participants in the study will be randomly assigned to receive either the study medication or placebo – an inactive substance designed to look like a medication.
Men and women ages 60-75 years old who have no memory and thinking difficulties and carry at least one copy of the ApoE4 gene.
If you are interested in learning more about the “Generation II” study, please call (401) 455-6402 or send an e-mail to:firstname.lastname@example.org. Ask about the “Generation II study.”